Work

Abstract CT001: Evaluation of pharmacodynamic and potential predictive biomarkers for GV20-0251, an anti-IGSF8 antibody, as monotherapy from ongoing Phase 1/2a study

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct001

Authors: Xingfeng Bao, Caibin Sheng, Inderjit Mehmi, Julio A. Peguero, Shivaani Kummar, Patricia LoRusso, Janice M. Mehnert, Aung Naing, Alexander I. Spira, Justin F. Gainor, Omid Hamid, Justin T. Moyers, Jin Wang, Xihao Wu, Hong Xiao, X. Shirley Liu, Tengfei Xiao, Kristopher Wentzel

Institutions: GV20 Therapeutics (United States), Angeles Clinic and Research Institute, Oregon Health & Science University, Yale University, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, The University of Texas MD Anderson Cancer Center, Virginia Cancer Specialists, Massachusetts General Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154742791

Cites:

Cited by:

Related to: